mitoxantrone has been researched along with Carcinoma, Epidermoid in 30 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 5.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Mitoxantrone was infused continuously in 21-day courses beginning every 6 weeks." | 2.68 | Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer. ( Aversa, S; Azzoni, P; Endrizzi, L; Fiorentino, MV; Koussis, H; Nicoletto, MO; Padrini, R; Palumbo, M; Rosabian, A, 1995) |
| "Twenty-six evaluable patients with advanced or recurrent squamous cell carcinoma of the uterine cervix were treated with mitoxantrone at a dosage of 12 mg/m2 every 3 weeks." | 2.66 | Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group. ( Bundy, B; Hatch, KD; Muss, HB; Sutton, GP, 1985) |
| "Gefitinib is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor." | 1.35 | Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines. ( Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q, 2009) |
| "Advanced squamous cell carcinomas of the head and neck region were often treated with combined radio-chemotherapy." | 1.33 | [Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies]. ( Alexiou, C; Bergemann, C; Erhardt, W; Iro, H; Jurgons, R; Parak, F; Schmid, R, 2005) |
| "In mice bearing transplants of a squamous cell carcinoma (ASB XIII), treatments with PCNU were followed by CRs in 3 of 38 animals on 15 mg/kg regimens and in 3 of 28 animals on 8 mg/kg regimens." | 1.33 | Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos. ( Baylouny, RA; Bissell, EC; Holiat, SM; Hubert, DD; Smith, WE; Sobel, HJ; Watts, LM; Yazdi, E, 2005) |
| "In the present study, we treated squamous cell carcinoma in rabbits with FFs bound to mitoxantrone (FF-MTX) that was concentrated with a magnetic field." | 1.31 | Locoregional cancer treatment with magnetic drug targeting. ( Alexiou, C; Arnold, W; Bergemann, C; Erhardt, W; Hulin, P; Klein, RJ; Lübbe, AS; Parak, FG; Wagenpfeil, S, 2000) |
| " Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment." | 1.29 | Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. ( Atwater, SW; Ciekot, PE; Elmslie, RE; Klein, MK; Moore, AS; Obradovich, JE; Ogilvie, GK; Salmon, MD; Straw, RC; Vail, DM, 1993) |
| "Leukopenia was mild, moderate, severe (1,000-1,999/mm3), and life-threatening (less than 1,000/mm3) in 17%, 23%, 42%, and 2% of courses, respectively." | 1.28 | Phase II trial of mitoxantrone in head and neck carcinoma. ( Ardalan, B; Benedetto, P; Desai, P; Feun, LG; Hussein, AM; Richman, SP; Savaraj, N; Sridhar, KS; Waldman, SM, 1991) |
| "Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals." | 1.28 | A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck. ( Levi, J; Page, J; Wheeler, H; Woods, RL, 1990) |
| "Mitoxantrone displays no activity in patients with advanced carcinoma of the vulva or vagina." | 1.28 | Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study. ( Bundy, BN; Christopherson, WA; Muss, HB, 1989) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 1.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| " Fifty-three evaluable patients were treated with this agent at a dosage of 5 mg/M2/week." | 1.27 | Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial. ( Birch, R; Gams, R; Velez-Garcia, E; Williams, SD, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (40.00) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, N | 1 |
| Yang, Y | 1 |
| Cai, CY | 1 |
| Lei, ZN | 1 |
| Wang, JQ | 1 |
| Gupta, P | 1 |
| Shukla, S | 2 |
| Ambudkar, SV | 2 |
| Kong, D | 1 |
| Chen, ZS | 2 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Chu, Q | 1 |
| Amano, O | 1 |
| Kanda, Y | 1 |
| Kunii, S | 1 |
| Wang, Q | 1 |
| Sakagami, H | 1 |
| Shi, Z | 1 |
| Tiwari, AK | 1 |
| Robey, RW | 1 |
| Singh, S | 1 |
| Kim, IW | 1 |
| Bates, SE | 1 |
| Peng, X | 1 |
| Abraham, I | 1 |
| Talele, TT | 1 |
| Fu, LW | 1 |
| Majeed, F | 1 |
| Javed, TA | 1 |
| Khan, AU | 1 |
| Koerber, RK | 1 |
| Alexiou, C | 3 |
| Jurgons, R | 2 |
| Schmid, R | 1 |
| Erhardt, W | 2 |
| Parak, F | 1 |
| Bergemann, C | 3 |
| Iro, H | 1 |
| Smith, WE | 1 |
| Hubert, DD | 1 |
| Yazdi, E | 1 |
| Holiat, SM | 1 |
| Bissell, EC | 1 |
| Watts, LM | 1 |
| Baylouny, RA | 1 |
| Sobel, HJ | 1 |
| Simon, C | 1 |
| Schmid, RJ | 1 |
| Kremer, M | 1 |
| Wanner, G | 1 |
| Huenges, E | 1 |
| Nawroth, T | 1 |
| Arnold, W | 2 |
| Parak, FG | 2 |
| Valdivieso, M | 1 |
| Umsawasdi, T | 1 |
| Spitzer, G | 1 |
| Chiuten, DF | 1 |
| Booser, DJ | 1 |
| Dhingra, HM | 1 |
| Bodey, GP | 1 |
| Joss, RA | 1 |
| Cavalli, F | 1 |
| Goldhirsch, A | 1 |
| Mermillod, B | 1 |
| Brunner, KW | 1 |
| Mattox, DE | 1 |
| Clark, GM | 1 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Oishi, N | 1 |
| Stuckey, WJ | 1 |
| De Jager, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Keiling, R | 1 |
| Fargeot, P | 1 |
| Bastit, P | 1 |
| van Glabbeke, M | 1 |
| Renard, J | 1 |
| Earl, H | 1 |
| Rubens, R | 1 |
| Alberts, DS | 1 |
| Peng, YM | 1 |
| Leigh, S | 1 |
| Davis, TP | 1 |
| Woodward, DL | 1 |
| Nicoletto, MO | 1 |
| Padrini, R | 1 |
| Koussis, H | 1 |
| Rosabian, A | 1 |
| Aversa, S | 1 |
| Endrizzi, L | 1 |
| Azzoni, P | 1 |
| Palumbo, M | 1 |
| Fiorentino, MV | 1 |
| Ogilvie, GK | 1 |
| Moore, AS | 1 |
| Obradovich, JE | 1 |
| Elmslie, RE | 1 |
| Vail, DM | 1 |
| Straw, RC | 1 |
| Salmon, MD | 1 |
| Klein, MK | 1 |
| Atwater, SW | 1 |
| Ciekot, PE | 1 |
| Lim, HJ | 1 |
| Masin, D | 1 |
| McIntosh, NL | 1 |
| Madden, TD | 1 |
| Bally, MB | 1 |
| Klein, RJ | 1 |
| Hulin, P | 1 |
| Wagenpfeil, S | 1 |
| Lübbe, AS | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Bigio, IJ | 1 |
| Mourant, JR | 1 |
| Los, G | 1 |
| Sridhar, KS | 1 |
| Hussein, AM | 1 |
| Benedetto, P | 1 |
| Waldman, SM | 1 |
| Feun, LG | 1 |
| Savaraj, N | 1 |
| Richman, SP | 1 |
| Ardalan, B | 1 |
| Desai, P | 1 |
| Schnabel, T | 1 |
| Zamboglou, N | 1 |
| Schmitt, G | 1 |
| Wheeler, H | 1 |
| Woods, RL | 1 |
| Page, J | 1 |
| Levi, J | 1 |
| Muss, HB | 2 |
| Bundy, BN | 1 |
| Christopherson, WA | 1 |
| Hoffmanns, HW | 1 |
| Altmeier, G | 1 |
| Stewart, DJ | 1 |
| Cripps, C | 1 |
| Maroun, JA | 1 |
| Hilgers, RD | 1 |
| Von Hoff, DD | 1 |
| Stephens, RL | 1 |
| Boutselis, JG | 1 |
| Hørding, U | 1 |
| Rose, C | 1 |
| Jakobsen, K | 1 |
| Dirksen, H | 1 |
| Sutton, GP | 1 |
| Bundy, B | 1 |
| Hatch, KD | 1 |
| Williams, SD | 1 |
| Birch, R | 1 |
| Velez-Garcia, E | 1 |
| Gams, R | 1 |
1 review available for mitoxantrone and Carcinoma, Epidermoid
| Article | Year |
|---|---|
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
4 trials available for mitoxantrone and Carcinoma, Epidermoid
| Article | Year |
|---|---|
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer.
Topics: Adult; Aged; CA-125 Antigen; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Cystade | 1995 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality T | 1985 |
26 other studies available for mitoxantrone and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2019 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Autophagy; Carcinoma, Squa | 2009 |
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cass | 2011 |
Primary squamous cell carcinoma of the prostate: a novel chemotherapy regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2002 |
[Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies].
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Drug | 2005 |
Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos.
Topics: Animals; Antineoplastic Agents; Asbestos, Serpentine; Aziridines; Benzoquinones; Carcinoma, Squamous | 2005 |
[Magnetic drug targeting. New paths for the local concentration of drugs for head and neck cancer].
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Magnetics | 2005 |
Targeting cancer cells: magnetic nanoparticles as drug carriers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Coated Materials, Biocompatible; Drug Carr | 2006 |
Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma | 1984 |
Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Femal | 1984 |
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom | 1984 |
Disposition of mitoxantrone in patients.
Topics: Adenocarcinoma; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Fe | 1983 |
Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
Topics: Animals; Anorexia; Carcinoma, Squamous Cell; Cat Diseases; Cats; Chemotherapy, Adjuvant; Dose-Respon | 1993 |
Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Dru | 2000 |
Locoregional cancer treatment with magnetic drug targeting.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Colloids; Drug Carriers; Drug Delivery Sys | 2000 |
Noninvasive, in-situ measurement of drug concentrations in tissue using optical spectroscopy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Hemoglobins; Mice; Mice, Nude | 1999 |
Phase II trial of mitoxantrone in head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Dose-Response R | 1991 |
[Intravenous mitoxantrone use and simultaneous radiotherapy as a palliative treatment in recurrent head and neck tumors].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy; Female; Head | 1991 |
A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck.
Topics: Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Mito | 1990 |
Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Carcinoma, Squamous Cell; Female; Humans; Infusions, In | 1989 |
[Local application of mitoxantrone in inoperable, stenosing esophageal carcinoma. Preliminary report].
Topics: Administration, Topical; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug | 1986 |
Phase II study of high-dose mitoxantrone in the treatment of recurrent squamous cell carcinoma of the head and neck.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Drug Evaluation; Drug Tolerance; Female; Head and | 1987 |
Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Middle Aged; | 1986 |
Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Hematologic Diseases; Humans; Middle | 1986 |
Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial.
Topics: Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Head and Neck Neop | 1985 |